Canaccord Genuity Group Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $160.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Canaccord Genuity Group from $158.00 to $160.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently commented on NBIX. Needham & Company LLC raised shares of Neurocrine Biosciences from […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Canaccord Genuity Group from $158.00 to $160.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently commented on NBIX. Needham & Company LLC raised shares of Neurocrine Biosciences from […]
